GlaxoSmithKline, Institute of Cancer at Barts, Queen Mary, University of London proteomics, inflammation news

The institute and the university spun out their cell signaling pathway technology into newco Activiomics Ltd. Activiomics will use its Targeted In-depth Quantification of Cell Signalling (TIQUAS) mass spectrometry platform to quantify phosphopeptides for biomarker discovery and drug profiling for biotech and pharmaceutical companies. ...